Arch Biopartners Inc. (ACHFF)
OTCMKTS · Delayed Price · Currency is USD
0.9700
-0.0200 (-2.02%)
Jan 20, 2026, 10:06 AM EST
Arch Biopartners Revenue
Arch Biopartners had revenue of 158.08K CAD in the quarter ending June 30, 2025. This brings the company's revenue in the last twelve months to -84.71K. In the fiscal year ending September 30, 2024, Arch Biopartners had annual revenue of 2.12M with 6.97% growth.
Revenue (ttm)
-84.71K CAD
Revenue Growth
+6.97%
P/S Ratio
-981.95
Revenue / Employee
n/a
Employees
n/a
Market Cap
60.99M USD
Revenue Chart
* This company reports financials in CAD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Sep 30, 2024 | 2.12M | 138.21K | 6.97% |
| Sep 30, 2023 | 1.98M | 1.02M | 105.63% |
| Sep 30, 2022 | 964.68K | -2.92M | -75.18% |
| Sep 30, 2021 | 3.89M | 3.82M | 5,625.22% |
| Sep 30, 2020 | 67.89K | -25.99K | -27.69% |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BioStem Technologies | 292.21M |
| LakeShore Biopharma | 84.75M |
| Nuo Therapeutics | 2.61M |
| Harvard Apparatus Regenerative Technology | 743.00K |
| Provectus Biopharmaceuticals | 350.44K |
| ZIVO Bioscience | 209.03K |
| Ayala Pharmaceuticals | 13.00K |
Arch Biopartners News
- 7 days ago - Arch Biopartners Names Patrick Vink As Chairman As Claude Allary Retires - Nasdaq
- 5 weeks ago - Arch Biopartners Announces Ethics Approval for St. Michael's Hospital to Participate in the Phase II Cardiac Surgery-Associated AKI Trial for LSALT Peptide - GlobeNewsWire
- 2 months ago - Arch Biopartners Closes Non-Brokered Private Placement - GlobeNewsWire
- 2 months ago - Arch biopartners launches non-brokered private placement - Seeking Alpha
- 2 months ago - Arch Biopartners Arranges Non-Brokered Private Placement - GlobeNewsWire
- 4 months ago - Arch Strengthens its Position as a Leading Kidney Therapeutics Company with the Acquisition of a Breakthrough Platform to Develop New Drugs Targeting Chronic Kidney Disease (CKD) - GlobeNewsWire
- 6 months ago - Arch Biopartners Announces First Patient Successfully Dosed at Toronto General Hospital in Phase II Trial of LSALT Peptide Targeting Cardiac Surgery-Associated Acute Kidney Injury - GlobeNewsWire
- 6 months ago - Arch Biopartners Announces Start of Patient Recruitment in Phase II PONTIAK Trial Targeting Drug-Toxin-Related Acute Kidney Injury (AKI) - GlobeNewsWire